Journal
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
Volume 60, Issue 1, Pages 55-67Publisher
HUMANA PRESS INC
DOI: 10.1007/s12016-020-08821-6
Keywords
Autoimmune diseases; Metabolism; Therapeutic target; Glycolysis; TCA cycle
Categories
Funding
- National Natural Science Foundation of China [81788101, 81630044, 81801627]
- Chinese Academy of Medical Science Innovation Fund for Medical Sciences [CIFMS2017-12M-1-008, 2016-12M-1-003, 2017-I2M-3-011, 2016-12M-1-008]
- Beijing Capital Health Development Fund [2020-2-4019]
- Construction Project of National Traditional Chinese Medicine Clinical Research Base of SATCM, and Clinical Cooperative Project of Chinese and Western Medicine for Major and Knotty Diseases of SATCM
- Fundamental Research Funds for the Central Universities [3332018026]
Ask authors/readers for more resources
Autoimmune diseases are characterized by abnormal immune responses and the signaling pathways controlling cell differentiation, death, and survival. Cell metabolism plays a crucial role in determining the function of different immune subsets. Studies exploring intervention strategies targeting key molecules of metabolic pathways in systemic lupus erythematosus and rheumatoid arthritis could provide potential drug targets for treating autoimmune diseases.
Autoimmune diseases (AIDs) are characterized with aberrant immune responses and their respective signaling pathways controlling cell differentiation, death, and survival. Cell metabolism is also an indispensable biochemical process that provides the very fundamental energy and materials. Accumulating evidences implicate that metabolism pathways have critical roles in determining the function of different immune subsets. Mechanisms of how immunometabolism participate in the pathogenesis of AIDs were also under intensive exploration. Here, in this review, we summarize the metabolic features of immune cells in AIDs and also the individual function of immunometabolism pathways, including glucose metabolism and tricarboxylic acid (TCA) cycle, in the setting of AIDs, mainly focusing on the potential targets for intervention. We also review studies that explore the intervention strategies targeting key molecules of metabolic pathways, such as mammalian target of rapamycin (mTOR), AMP-activated protein kinase (AMPK), and hypoxia-inducible factor 1a (HIF1a), in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The highlight of this review is to provide a comprehensive summary of the status quo of immunometabolism studies in AIDs and the potential translatable drug targets.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available